Important Deadlines for Ottawa NMD 2023

The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th

The Ottawa NMD 2023 Conference will feature top international basic and clinical neuromuscular (NMD) researchers highlighting advances in neuromuscular disease research and clinical care, including novel diagnostic techniques, disease pathogenesis, basic muscle and stem cell biology, and promising therapies to treat these devastating disorders. Sessions will be organized to include basic, translational and clinical presentations to engage all attendees, regardless of background or training. New for  this year are more clinical sessions and Continuing Medical Education (CME) credits!

Please visit the Ottawa NMD 2023 website for the latest information about the conference including updates to the confirmed speaker list.

NMD4C Annual Meeting to Take Place Directly Before Ottawa NMD 2023

The NMD4C Annual Meeting will take place in Ottawa during the day on Thursday September 7th before Ottawa NMD 2023 begins. The NMD4C meeting will be an opportunity to share your input on the network’s future activities, discuss emerging topics in NMDs, recognize NMD4C early-career awardees and funding recipients, and network with Canadian neuromuscular clinicians and researchers. Don’t miss this opportunity to attend both events! More information on the NMD4C Annual Meeting is available here.

Ottawa NMD conference poster

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.